Margaret Kaczor
Stock Analyst at William Blair
(0.56)
# 4,071
Out of 5,072 analysts
24
Total ratings
35.71%
Success rate
-17.32%
Average return
Main Sectors:
Stocks Rated by Margaret Kaczor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $26.52 | - | 2 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Upgrades: Outperform | n/a | $9.82 | - | 3 | Jan 14, 2025 | |
| CBLL CeriBell | Initiates: Outperform | n/a | $16.97 | - | 1 | Nov 5, 2024 | |
| STIM Neuronetics | Downgrades: Market Perform | n/a | $1.47 | - | 4 | Aug 12, 2024 | |
| INGN Inogen | Upgrades: Outperform | n/a | $7.17 | - | 5 | Feb 15, 2024 | |
| SKIN The Beauty Health Company | Downgrades: Market Perform | n/a | $1.48 | - | 2 | Nov 14, 2023 | |
| DVA DaVita | Downgrades: Market Perform | n/a | $119.68 | - | 2 | Sep 11, 2019 | |
| MDT Medtronic | Assumes: Market Perform | n/a | $105.33 | - | 1 | Jun 6, 2018 | |
| ABT Abbott Laboratories | Upgrades: Outperform | n/a | $128.90 | - | 3 | Jan 25, 2018 | |
| DXCM DexCom | Initiates: Outperform | n/a | $63.47 | - | 1 | Apr 27, 2017 |
STAAR Surgical Company
Feb 12, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $26.52
Upside: -
CVRx, Inc.
Jan 14, 2025
Upgrades: Outperform
Price Target: n/a
Current: $9.82
Upside: -
CeriBell
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $16.97
Upside: -
Neuronetics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $7.17
Upside: -
The Beauty Health Company
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.48
Upside: -
DaVita
Sep 11, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $119.68
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $105.33
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $128.90
Upside: -
DexCom
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $63.47
Upside: -